Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.
Alexander R GuptaGavitt A WoodardDavid M JablonsMichael J MannJohannes R KratzPublished in: Future oncology (London, England) (2021)
There remains a critical need for improved staging of non-small-cell lung cancer, as recurrence and mortality due to undetectable metastases at the time of surgery remain high even after complete resection of tumors currently categorized as 'early stage.' A 14-gene quantitative PCR-based expression profile has been extensively validated to better identify patients at high-risk of 5-year mortality after surgical resection than conventional staging - mortality that almost always results from previously undetectable metastases. Furthermore, prospective studies now suggest a predictive benefit in disease-free survival when the assay is used to guide adjuvant chemotherapy decisions in early-stage non-small-cell lung cancer patients.
Keyphrases
- early stage
- free survival
- lymph node
- pet ct
- cardiovascular events
- high throughput
- sentinel lymph node
- minimally invasive
- single cell
- multidrug resistant
- risk factors
- cell therapy
- stem cells
- copy number
- type diabetes
- gene expression
- cardiovascular disease
- squamous cell carcinoma
- mass spectrometry
- acute coronary syndrome
- glycemic control
- rectal cancer
- genome wide identification